STI Screening Guidelines: A Focus on Trichomonas, Chlamydia, and Gonorrhea

Jane R. Schwebke, MD
Professor of Medicine/Infectious Diseases
University of Alabama at Birmingham
Birmingham, AL

Identified or perceived conflict of interest has been resolved in accordance with ACCME guidelines.

Faculty Disclosure

Consulting Fees: Hologic, Talis
Contracted Research: BD Diagnostics, Hologic, Lupin, Mycovia Pharmaceuticals, Synexis
Ownership Interest: Talis
Objectives

- Describe the recent surge in incidence rates for common, largely preventable STIs and the major population health challenge they represent
- Formulate clinical strategies to overcome current low screening rates for STIs in at-risk and general populations, using the most sensitive available laboratory molecular technology
- Apply counseling techniques in their medical practice that encourages physician/patient engagement in STI prevention discussions

Chlamydia Trachomatis
Chlamydia — Rates of Reported Cases by Sex, United States, 2000–2017

NOTE: Data collection for chlamydia began in 1984 and chlamydia was made nationally notifiable in 1995; however, chlamydia was not reportable in all 50 states and the District of Columbia until 2000. Refer to the National Notifiable Disease Surveillance System (NNDSS) website for more information: https://wwwn.cdc.gov/nndss/conditions/chlamydia-trachomatis-infection/.

Pelvic Inflammatory Disease—Hospitalizations of Women Aged 15–44 Years, United States, 2000–2009

NOTE: The relative standard errors for acute and unspecified pelvic inflammatory disease (PID) cases ranges from 8%–18%. The relative standard error for chronic PID cases ranges from 12%–28%. Data only available through 2009. SOURCE: 2009 National Hospital Discharge Survey [Internet]. Atlanta: Centers for Disease Control and Prevention. Available from: http://www.cdc.gov/nchs/nhds/about/nhds.htm.
Provider Screening Compliance is Low
Percentage of sexually active females aged 16–24 years who were screened for *Chlamydia trachomatis* infection, by health plan type and year--- Healthcare Effectiveness and Data Information Set, United States--2009-2015

Division of STD Prevention, CDC

Neisseria Gonorrhoeae

STI Screening Guidelines:
A Focus on Trichomonas, Chlamydia, and Gonorrhea
Neisseria gonorrhoeae - Percentage of isolates with decreased susceptibility or resistance to extended-spectrum cephalosporins (cefixime and/or ceftriaxone) according to the most recent World Health Organization Gonococcal Antimicrobial Surveillance Programme.

*2014 data for most countries, but for a few countries, only 2011–2013 data were available.

**NOTE:** Isolates not tested for cefixime susceptibility in 2008.
Vaginitis/Vaginosis

*Trichomonas*

U.S. Estimates of Trichomoniasis Prevalence and Incidence

Estimated prevalence of sexually transmitted infections in the US (total 110,197,000)

Estimated new sexually transmitted infections in the US each year (total 19,738,800)

STI Screening Guidelines:
A Focus on Trichomonas, Chlamydia, and Gonorrhea
STI Screening Guidelines:
A Focus on Trichomonas, Chlamydia, and Gonorrhea
## M. genitalium Disease Associations

<table>
<thead>
<tr>
<th>Syndrome</th>
<th>Summary risk estimate</th>
<th>Studies accounting for CT (subset)</th>
</tr>
</thead>
<tbody>
<tr>
<td>NGU</td>
<td>5.5 (4.3 – 7.0)</td>
<td>-</td>
</tr>
<tr>
<td>Female Urethritis</td>
<td>2.2 (1.6 – 2.9)</td>
<td>2.1 (1.5 – 2.9)</td>
</tr>
<tr>
<td>Cervicitis</td>
<td>1.6 (1.4 – 2.0)</td>
<td>1.9 (1.4 – 2.8)</td>
</tr>
<tr>
<td>PID / Endometritis</td>
<td>1.9 (1.3 – 3.5)</td>
<td>2.0 (0.95 – 4.0)</td>
</tr>
<tr>
<td>Preterm Delivery</td>
<td>1.9 (1.2 – 2.9)</td>
<td>2.3 (1.1 – 5.0)</td>
</tr>
<tr>
<td>Spontaneous Abortion</td>
<td>1.8 (1.1 – 3.0)</td>
<td>2.3 (1.0 – 4.9)</td>
</tr>
<tr>
<td>Infertility</td>
<td>3.0 (1.3 – 6.7)</td>
<td>3.7 (1.7 – 8.1)</td>
</tr>
<tr>
<td>HIV</td>
<td>2.0 (1.4 – 2.8)</td>
<td>-</td>
</tr>
</tbody>
</table>

Taylor-Robinson & Jensen, Clin Microbiol Rev 2011; Lis et al., CID 2015 – updated; Mavedzenge, AIDS 2009

---

**STI Screening Guidelines:**

**A Focus on Trichomonas, Chlamydia, and Gonorrhea**
M. genitalium - Macrolide Resistance Mutations (MRMs)*

Worldwide, reported MG MRM prevalence ranges from 4%-100%, mostly in the 15%-60% range

MG MRM prevalence ranges from 44%-90% across U.S. sites

7 U.S. cities
- Seattle, WA
  62% (hetero men)¹
  69% (men w/urethritis)²
  94% (MSM)³
- Los Angeles, CA
  80% (clinic attendees)⁴
- New Orleans, LA
  60% (men w/urethritis)²
- Pittsburgh, PA
  58% (men w/urethritis)²
- Durham & Greensboro, NC
  61% & 64% (men w/urethritis)²
- Birmingham, AL
  44% (STD Clinic)⁴
  61% (hetero couples)³
  61% (men w/urethritis)²
  74% (HIV+ MSM)⁵
- 7 U.S. cities
  48% (clinic attendees)³

*MRMs in the 23S rRNA gene, typically A2071 and A2072 (E.coli numbering 2058 and 2059)


Some Slide Material Courtesy of Lisa Manhart

M. genitalium – Macrolide Resistance Mutations (MRMs)*

Worldwide, reported MG MRM prevalence ranges from 4%-100%, mostly in the 15%-60% range

MG MRM prevalence ranges from 44%-90% across U.S. sites

7 U.S. cities
- Seattle, WA
  62% (hetero men)¹
  69% (men w/urethritis)²
  94% (MSM)³
- Los Angeles, CA
  80% (clinic attendees)⁴
- New Orleans, LA
  60% (men w/urethritis)²
- Pittsburgh, PA
  58% (men w/urethritis)²
- Durham & Greensboro, NC
  61% & 64% (men w/urethritis)²
- Birmingham, AL
  44% (STD Clinic)⁴
  61% (hetero couples)³
  61% (men w/urethritis)²
  74% (HIV+ MSM)⁵
- 7 U.S. cities
  48% (clinic attendees)³

*MRMs in the 23S rRNA gene, typically A2071 and A2072 (E.coli numbering 2058 and 2059)


Some Slide Material Courtesy of Lisa Manhart

STI Screening Guidelines:
A Focus on Trichomonas, Chlamydia, and Gonorrhea